Moderna’s stock falls after data shows biotech’s RSV vaccine trails rivals after 18 months

Moderna Inc.’s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.